Posted: 12 May 2023
Amplia Therapeutics Limited, is pleased to announce completion of enrolment of the third cohort of patients in the ongoing Phase 1b/2a ACCENT clinical trial in frontline patients with pancreatic cancer.
Amplia’s CEO and Managing Director Dr Chris Burns commented: “We are very pleased to have completed recruitment of Cohort 3, despite the disruption of holidays in April. This achievement reflects the enthusiasm and commitment of the clinical trial sites in Melbourne, Sydney and Brisbane which has allowed recruitment for this cohort to be completed within one month of opening enrolment. As always, we thank the patients for consenting to be part of the trial.”
The first stage of the ACCENT trial is designed to test ascending doses of AMP945 given in combination with standard-of-care chemotherapy of gemcitabine and nab-paclitaxel, in patients with advanced pancreatic cancer. After 1 month of treatment, the trial’s Safety Committee will review the clinical data collected and, subject to the data, determine next steps in the trial.
